Ionis Pharmaceuticals, Inc.
MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
Last updated:
Abstract:
Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.
Status:
Application
Type:
Utility
Filling date:
28 May 2019
Issue date:
20 Feb 2020